Semnur Pharmaceuticals, Inc.

Semnur Pharmaceuticals, Inc., trading under ticker DECA, represents the post-merger operating company formed through the business combination with Decathlon Alpha IV, Corp., a blank-check vehicle sponsored by Decathlon Capital Partners that completed its IPO in 2021 targeting the healthcare and biopharmaceutical sector. The company filed a Form 10-Q with the SEC on November 16, 2022, covering quarterly results as the combined entity continued operating under the DECA ticker following the de-SPAC transaction. Semnur focuses on clinical-stage pharmaceutical development, reflecting the healthcare mandate of the original Decathlon Alpha IV vehicle. For full filing history, deal terms, and ongoing status updates on DECA and hundreds of other SPAC transactions, sign up for complete data access at SpacDesk.